You Position: Home > Paper
Advanced Non-small Cell Lung Cancer with Acquired RET Fusion After ALK-TKI Resistance:A Case Report and Literature Review
( views:1, downloads:1 )
- Author:
- No author available
- Journal Title:
- Cancer Research on Prevention and Treatment
- Issue:
- 8
- DOI:
- 10.3971/j.issn.1000-8578.2024.24.0131
- Key Word:
- ALK-TKI耐药;RET融合;CCDC6;非小细胞肺癌;靶向治疗
Abstract： 0 引言间变性淋巴瘤激酶(anaplastic lymphoma kin-ase,ALK)基因融合阳性是非小细胞肺癌(non-small cell lung cancer,NSCLC)中常见的驱动基因突变类型之一.ALK融合阳性NSCLC发生率较低,只见于约3％～5％的NSCLC,且患者接受ALK-TKI靶向治疗预后较好,因此,ALK基因突变也被称为"钻石突变".即便如此,携带ALK基因表达的患者仍会进展[1-2],且通常与ALK-TKI耐药相关. ALK-TKI耐药主要包括原发性耐药和获得性耐药,前者的机制目前尚不明确,初步考虑与肿瘤内在因素、患者及药物特异性因素有关.后者又分为ALK依赖型和ALK非依赖型耐药[3].
- This article has no references!